## Elaine T Alarid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6906013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abstract P5-11-01: Identification of novel ER and ER-NFκB driven stem-like cell populations in ER+ breast cancer. Cancer Research, 2022, 82, P5-11-01-P5-11-01.	0.9	Ο
2	Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Research, 2022, 24, 19.	5.0	6
3	Collagen I Fibrous Substrates Modulate the Proliferation and Secretome of Estrogen Receptor-Positive Breast Tumor Cells in a Hormone-Restricted Microenvironment. ACS Biomaterials Science and Engineering, 2021, 7, 2430-2443.	5.2	4
4	Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1. Hormones and Cancer, 2020, 11, 129-147.	4.9	22
5	Modeling chemical effects on breast cancer: the importance of the microenvironment in vitro. Integrative Biology (United Kingdom), 2020, 12, 21-33.	1.3	9
6	The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers. Molecular Cancer Research, 2020, 18, 1018-1027.	3.4	31
7	Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity. Endocrinology, 2019, 160, 2427-2440.	2.8	4
8	Grainyhead-like Protein 2: The Emerging Role in Hormone-Dependent Cancers and Epigenetics. Endocrinology, 2019, 160, 1275-1288.	2.8	13
9	Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model. FASEB Journal, 2019, 33, 8623-8633.	0.5	23
10	The Phosphorylated Estrogen Receptor <i>α</i> (ER) Cistrome Identifies a Subset of Active Enhancers Enriched for Direct ER-DNA Binding and the Transcription Factor GRHL2. Molecular and Cellular Biology, 2019, 39, .	2.3	20
11	17β-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes. Journal of the Endocrine Society, 2018, 2, 293-309.	0.2	9
12	Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model. Scientific Reports, 2018, 8, 7139.	3.3	35
13	Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. , 2016, 165, 79-92.		60
14	Progress towards understanding heterotypic interactions in multi-culture models of breast cancer. Integrative Biology (United Kingdom), 2016, 8, 684-692.	1.3	14
15	Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments. Biomedical Microdevices, 2016, 18, 70.	2.8	19
16	A kinetic model identifies phosphorylated estrogen receptorâ€Î± (ERα) as a critical regulator of ERα dynamics in breast cancer. FASEB Journal, 2015, 29, 2022-2031.	0.5	10
17	Ubiquitylation of nuclear receptors: new linkages and therapeutic implications. Journal of Molecular Endocrinology, 2015, 54, R151-R167.	2.5	34
18	Peptidylprolyl Isomerase Pin1 Directly Enhances the DNA Binding Functions of Estrogen Receptor α. Journal of Biological Chemistry, 2015, 290, 13749-13762.	3.4	17

Elaine T Alarid

#	Article	IF	CITATIONS
19	Streamlining gene expression analysis: integration of co-culture and mRNA purification. Integrative Biology (United Kingdom), 2014, 6, 224.	1.3	14
20	Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity. Integrative Biology (United Kingdom), 2013, 5, 807.	1.3	27
21	The Proteasome Inhibitor Bortezomib Induces an Inhibitory Chromatin Environment at a Distal Enhancer of the Estrogen Receptor-α Gene. PLoS ONE, 2013, 8, e81110.	2.5	12
22	Regulation of Estrogen Receptor <i>α</i> N-Terminus Conformation and Function by Peptidyl Prolyl Isomerase Pin1. Molecular and Cellular Biology, 2012, 32, 445-457.	2.3	64
23	Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. Journal of Clinical Oncology, 2011, 29, 2978-2984.	1.6	71
24	Repression of <i>ESR1</i> through Actions of Estrogen Receptor Alpha and Sin3A at the Proximal Promoter. Molecular and Cellular Biology, 2009, 29, 4949-4958.	2.3	68
25	Temporal variation in estrogen receptor-α protein turnover in the presence of estrogen. Journal of Molecular Endocrinology, 2008, 40, 23-34.	2.5	57
26	Altered Target Gene Regulation Controlled by Estrogen Receptor-Î $\pm$ Concentration. Molecular Endocrinology, 2006, 20, 291-301.	3.7	45
27	Lives and Times of Nuclear Receptors. Molecular Endocrinology, 2006, 20, 1972-1981.	3.7	64
28	Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor α N Terminus. Molecular and Cellular Biology, 2005, 25, 5417-5428.	2.3	97
29	Increases in estrogen receptorâ€Î± concentration in breast cancer cells promote serine 118/104/106â€independent AFâ€1 transactivation and growth in the absence of estrogen. FASEB Journal, 2004, 18, 81-93.	0.5	69
30	Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-α. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E891-E898.	3.5	84
31	Proteasome-Mediated Proteolysis of Estrogen Receptor: A Novel Component in Autologous Down-Regulation. Molecular Endocrinology, 1999, 13, 1522-1534.	3.7	265
32	Proteasome-Mediated Proteolysis of Estrogen Receptor: A Novel Component in Autologous Down-Regulation. Molecular Endocrinology, 1999, 13, 1522-1534.	3.7	84